Bavarian Nordic (BAVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bavarian Nordic (BAVA) has a cash flow conversion efficiency ratio of 0.042x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr545.05 Million ≈ $85.28 Million USD) by net assets (Dkr12.87 Billion ≈ $2.01 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Bavarian Nordic worth for the company's overall valuation and market capitalisation.
Bavarian Nordic - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Bavarian Nordic's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bavarian Nordic Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bavarian Nordic ranked by their cash flow conversion efficiency. Explore Bavarian Nordic earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Voltronic Power Technology Corp
TW:6409
|
0.046x |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
0.177x |
|
Tenable Holdings Inc
NASDAQ:TENB
|
0.354x |
|
Asker Healthcare
ST:ASKER
|
0.013x |
|
Newell Brands Inc
NASDAQ:NWL
|
0.012x |
|
CNNC Hua Yuan Titanium Dioxide Co Ltd
SHE:002145
|
0.002x |
|
Central Puerto S.A.
BA:CEPU
|
0.014x |
|
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Bavarian Nordic (2001–2025)
The table below shows the annual cash flow conversion efficiency of Bavarian Nordic from 2001 to 2025. View current stock price of Bavarian Nordic for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Dkr12.87 Billion ≈ $2.01 Billion |
Dkr2.72 Billion ≈ $425.86 Million |
0.211x | +23.74% |
| 2024-12-31 | Dkr11.41 Billion ≈ $1.78 Billion |
Dkr1.95 Billion ≈ $305.07 Million |
0.171x | +57.90% |
| 2023-12-31 | Dkr10.34 Billion ≈ $1.62 Billion |
Dkr1.12 Billion ≈ $175.11 Million |
0.108x | +251.70% |
| 2022-12-31 | Dkr7.15 Billion ≈ $1.12 Billion |
Dkr220.05 Million ≈ $34.43 Million |
0.031x | +163.31% |
| 2021-12-31 | Dkr7.37 Billion ≈ $1.15 Billion |
Dkr-358.50 Million ≈ $-56.09 Million |
-0.049x | -141.60% |
| 2020-12-31 | Dkr4.89 Billion ≈ $765.76 Million |
Dkr571.91 Million ≈ $89.48 Million |
0.117x | +179.00% |
| 2019-12-31 | Dkr1.87 Billion ≈ $291.86 Million |
Dkr-275.91 Million ≈ $-43.17 Million |
-0.148x | -11.78% |
| 2018-12-31 | Dkr2.18 Billion ≈ $341.18 Million |
Dkr-288.53 Million ≈ $-45.14 Million |
-0.132x | -253.48% |
| 2017-12-31 | Dkr2.51 Billion ≈ $392.13 Million |
Dkr216.06 Million ≈ $33.80 Million |
0.086x | -35.01% |
| 2016-12-31 | Dkr2.02 Billion ≈ $315.61 Million |
Dkr267.60 Million ≈ $41.87 Million |
0.133x | +69.09% |
| 2015-12-31 | Dkr1.34 Billion ≈ $210.04 Million |
Dkr105.32 Million ≈ $16.48 Million |
0.078x | -71.00% |
| 2014-12-31 | Dkr1.25 Billion ≈ $195.90 Million |
Dkr338.75 Million ≈ $53.00 Million |
0.271x | +79.58% |
| 2013-12-31 | Dkr976.29 Million ≈ $152.75 Million |
Dkr147.08 Million ≈ $23.01 Million |
0.151x | +649.29% |
| 2012-12-31 | Dkr999.68 Million ≈ $156.41 Million |
Dkr20.10 Million ≈ $3.14 Million |
0.020x | +106.47% |
| 2011-12-31 | Dkr1.21 Billion ≈ $188.94 Million |
Dkr-375.24 Million ≈ $-58.71 Million |
-0.311x | -4.99% |
| 2010-12-31 | Dkr810.43 Million ≈ $126.80 Million |
Dkr-239.86 Million ≈ $-37.53 Million |
-0.296x | +56.95% |
| 2009-12-31 | Dkr704.21 Million ≈ $110.18 Million |
Dkr-484.14 Million ≈ $-75.75 Million |
-0.687x | -3214.05% |
| 2008-12-31 | Dkr1.02 Billion ≈ $158.82 Million |
Dkr22.41 Million ≈ $3.51 Million |
0.022x | -83.52% |
| 2007-12-31 | Dkr1.22 Billion ≈ $190.51 Million |
Dkr163.16 Million ≈ $25.53 Million |
0.134x | +147.63% |
| 2006-12-31 | Dkr691.40 Million ≈ $108.17 Million |
Dkr-194.49 Million ≈ $-30.43 Million |
-0.281x | -204.50% |
| 2005-12-31 | Dkr630.10 Million ≈ $98.58 Million |
Dkr-58.21 Million ≈ $-9.11 Million |
-0.092x | +61.98% |
| 2004-12-31 | Dkr315.39 Million ≈ $49.35 Million |
Dkr-76.63 Million ≈ $-11.99 Million |
-0.243x | -40386.52% |
| 2003-12-31 | Dkr347.00 Million ≈ $54.29 Million |
Dkr209.27K ≈ $32.74K |
0.001x | +100.86% |
| 2002-12-31 | Dkr196.44 Million ≈ $30.73 Million |
Dkr-13.71 Million ≈ $-2.15 Million |
-0.070x | +96.69% |
| 2001-12-31 | Dkr44.14 Million ≈ $6.91 Million |
Dkr-93.12 Million ≈ $-14.57 Million |
-2.109x | -- |
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an or… Read more